Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,773 across all filing types
Latest filing 2023-10-01 Investor Presentation
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Company Presentation October 2023 (English)
Investor Presentation Classification · 1% confidence The document is titled "# *General company presentation*" and contains extensive slides detailing company strategy, scientific leadership, partnership updates (including financial terms like upfront payments and royalties), pipeline status (PhI, PhII, PhIII), and key performance indicators (KPIs) presented in a visual, slide-deck format. This structure, combined with the forward-looking statements and focus on strategy and pipeline, strongly indicates an Investor Presentation (IP) used to communicate with current and potential investors. It is not a formal regulatory filing like a 10-K, nor is it a brief earnings release (ER). The length (over 41k characters) suggests it is a comprehensive presentation, not just a short announcement (RPA).
2023-10-01 German
Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
Regulatory Filings Classification · 1% confidence The document is a news release dated September 27, 2023, announcing a 'partnering agreement to strengthen biotech innovators in shared R&D economy' involving Evotec SE and several lab/incubator entities. It details a strategic collaboration rather than reporting periodic financial results (like 10-K or IR), management changes (MANG), or insider trades (DIRS). It is a general corporate announcement about a business development. Since it is not a specific regulatory filing like a 10-K, DEF 14A, or a specific financial report, and it is not a short announcement pointing to a separate report (RPA), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous corporate news item distributed via EQS News, which is often used for non-standard, material announcements.
2023-09-27 English
Evotec and Novo Nordisk launch LAB eN2 to accelerate translation in cardiometabolic diseases
Environmental & Social Information Classification · 1% confidence The document is a news release dated September 26, 2023, originating from Evotec SE and distributed via EQS News. It announces a new collaboration, 'LAB eN²', with Novo Nordisk to accelerate drug discovery in cardiometabolic diseases. The text structure, use of 'EQS-News', date/time stamps, and the nature of the announcement (a strategic partnership/initiative) strongly suggest this is a general corporate news release. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific report (AR, IR), and it is announcing a business development rather than a change in management (MANG) or a capital event (CAP/SHA), the most appropriate classification is the general regulatory announcement/news category, which aligns best with RNS (Regulatory News Service/Announcements) or potentially a general news item if RNS is interpreted broadly as the distribution channel for non-standard filings. Given the options, RNS serves as the best fit for a standard corporate press release distributed through a regulatory news wire service that doesn't fit a more specific category like ER or CT.
2023-09-26 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It reports a change in the percentage of voting rights held by T. Rowe Price International Funds, Inc. (crossing the 5% threshold). This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds.
2023-09-25 English
Half-yearly financial report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'HALF-YEAR REPORT 2023' and contains comprehensive financial statements, income statements, segment information, and detailed management analysis of the company's performance for the first six months of the fiscal year. It is not an announcement or a summary, but the full interim report itself, fitting the definition of an Interim / Quarterly Report (IR). H2 2023
2023-08-31 English
Evotec SE reports results for the first half-year 2023 and provides corporate updates
Earnings Release Classification · 1% confidence The document explicitly states it reports 'results for the first half-year 2023' and contains detailed financial highlights, segment information, and guidance updates for the full year. The keyword 'Half Year Report' is present. This content structure is characteristic of a comprehensive financial report covering a period shorter than a full year. Therefore, it aligns best with the Interim / Quarterly Report definition (IR). It is not just an announcement of a report (RPA) because it contains the actual summarized results and tables, despite also mentioning a webcast. H1 2023
2023-08-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.